UBS maintains Vertex Pharmaceuticals at Buy, raises price target to $640 from $615

What happened

UBS kept its Buy rating on Vertex Pharmaceuticals and raised its price target to $640 from $615, a 4.1% increase. The new target implies 15.7% upside from the November 2 close of $553.15.

Confirmed

Global impact / market context

A higher price target signals that UBS expects more value from Vertex shares ahead. For investors, this supports confidence in the stock, while the mix of ratings shows analysts do not all agree on how much upside remains.

Analyst inference

Recent analyst targets for Vertex range from $563 to $650 across five notes. That range shows differing views on growth and risk. The average view leans positive, but the Hold rating and lower targets remind investors that opinions vary.

Analyst inference

What to watch

1. Watch whether other analysts change their Vertex price targets after UBS raised its target to $640 from $615. Confirmed
2. Track Vertex announcements on drug sales, trial results, and spending plans, since these can support or challenge the higher target and shape future revenue and costs. Proposed
3. Compare the stock price with the $640 target; narrowing upside could lead analysts to lower targets, while wider upside may bring upgrades and draw more investor money into the stock. Analyst inference

Evidence

• Original source link unavailable